Technical Analysis for KZIA - Kazia Therapeutics Limited
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 10.2 | 0.00% | 0.00 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Historical KZIA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Crossed Above 20 DMA | Bullish | -2.76% | |
| Pocket Pivot | Bullish Swing Setup | -2.76% | |
| Stochastic Reached Oversold | Weakness | -2.76% | |
| Oversold Stochastic | Weakness | -2.76% | |
| 20 DMA Resistance | Bearish | 2.10% | |
| MACD Bearish Signal Line Cross | Bearish | 2.10% | |
| 50 DMA Support | Bullish | 2.10% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 20 DMA Resistance | about 19 hours ago | |
| Up 1% | about 19 hours ago | |
| 20 DMA Support | about 20 hours ago | |
| 60 Minute Opening Range Breakout | about 20 hours ago | |
| Down 3% | about 23 hours ago |
Get a Trading Assistant
- Earnings date: 01/23/2019
Kazia Therapeutics Limited Description
Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer ATM Cancer Treatments Chemotherapy Ovarian Cancer Blastoma Cancer Treatment Cancer Cell Glioma Neuroblastoma Cytoskeleton Novogen Pharmaceutical Research Diffuse Intrinsic Pontine Glioma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 15.85 |
| 52 Week Low | 2.47 |
| Average Volume | 155,010 |
| 200-Day Moving Average | 6.85 |
| 50-Day Moving Average | 9.98 |
| 20-Day Moving Average | 10.49 |
| 10-Day Moving Average | 10.72 |
| Average True Range | 1.01 |
| ADX | 43.93 |
| +DI | 30.23 |
| -DI | 17.22 |
| Chandelier Exit (Long, 3 ATRs ) | 10.17 |
| Chandelier Exit (Short, 3 ATRs ) | 12.36 |
| Upper Bollinger Band | 11.72 |
| Lower Bollinger Band | 9.26 |
| Percent B (%b) | 0.38 |
| BandWidth | 23.43 |
| MACD Line | 0.15 |
| MACD Signal Line | 0.22 |
| MACD Histogram | -0.0778 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 11.04 | ||||
| Resistance 3 (R3) | 11.08 | 10.85 | 10.90 | ||
| Resistance 2 (R2) | 10.85 | 10.63 | 10.82 | 10.85 | |
| Resistance 1 (R1) | 10.52 | 10.50 | 10.41 | 10.48 | 10.81 |
| Pivot Point | 10.29 | 10.29 | 10.23 | 10.27 | 10.29 |
| Support 1 (S1) | 9.96 | 10.07 | 9.85 | 9.92 | 9.59 |
| Support 2 (S2) | 9.73 | 9.94 | 9.71 | 9.55 | |
| Support 3 (S3) | 9.40 | 9.73 | 9.50 | ||
| Support 4 (S4) | 9.36 |
